within Pharmacolibrary.Drugs.ATC.N;

model N06BX16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 7.983333333333333e-05,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06BX16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pramiracetam is a synthetic nootropic compound in the racetam family, developed in the late 1970s. It is used for cognitive enhancement and has been studied for potential benefits in memory impairment and dementia; however, it is not approved by the FDA for use in the United States and is available as a prescription drug in a few countries such as Italy and some Eastern European countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers (male and female), single oral administration.</p><h4>References</h4><ol><li><p>Chang, T, et al., &amp; Yakatan, GJ (1985). Pharmacokinetics of oral pramiracetam in normal volunteers. <i>Journal of clinical pharmacology</i> 25(4) 291–295. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1985.tb02841.x\">10.1002/j.1552-4604.1985.tb02841.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4008675/\">https://pubmed.ncbi.nlm.nih.gov/4008675</a></p></li><li><p>Auteri, A, et al., &amp; Urso, R (1992). Pharmacokinetics of pramiracetam in healthy volunteers after oral administration. <i>International journal of clinical pharmacology research</i> 12(3) 129–132. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1473879/\">https://pubmed.ncbi.nlm.nih.gov/1473879</a></p></li><li><p>Parnetti, L (1995). Clinical pharmacokinetics of drugs for Alzheimer&#x27;s disease. <i>Clinical pharmacokinetics</i> 29(2) 110–129. DOI:<a href=\"https://doi.org/10.2165/00003088-199529020-00005\">10.2165/00003088-199529020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7586900/\">https://pubmed.ncbi.nlm.nih.gov/7586900</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06BX16;
